Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mixed session - Melanoma

Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC)

Date

24 Nov 2019

Session

Mixed session - Melanoma

Presenters

Alison Weppler

Citation

Annals of Oncology (2019) 30 (suppl_9): ix115-ix117. 10.1093/annonc/mdz429

Authors

A.M. Weppler1, P. Bhave1, P. De Ieso2, M. Chua2, J. Raleigh3, A. Hatzimihalis3, A. Gill4, S. Balachander5, J. Callahan6, A. Pattison5, A. Caneborg5, G. Au Yeung1, G. McArthur1, R.J. Hicks6, R. Tothill5, S.K. Sandhu1

Author affiliations

  • 1 Medical Oncology, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 2 Radiation Oncology, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 3 Centre For Cancer Research, University of Melbourne, 3000 - Melbourne/AU
  • 4 Kolling Institute Of Medical Research And The Department Of Anatomical Pathology, Royal North Shore Hospital, 2065 - Sydney/AU
  • 5 Department Of Clinical Pathology And Centre For Cancer Research, University of Melbourne, 3000 - Melbourne/AU
  • 6 Department Of Nuclear Medicine, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.